ArticleFrontiers in oncology2025
Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioimmunoblastic T cell lymphoma (AITL) is classified as a nodal T-cell lymphoma from T follicular helper(Tfh) cells. Dysfunctional Tfh cells can lead to abnormal B cell regulation and plasma cell differentiation in AITL. However, the coexistence of AITL with plasma cell tumors is exceedingly rare. Here, we report three patients diagnosed with AITL accompanied by monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). The clinicopathologic findings, together with a review of previously reported cases, provide insight into the possible biological relationship between AITL and plasma-cell neoplasms. Epstein-Barr virus (EBV) infection was detected in all cases, suggesting a potential-though unproven-association between EBV-driven immune dysregulation and plasma-cell proliferation. Case analysis showed that some monoclonal plasma cells originated from the interior of AITL, while others originated from the bone marrow. This indicated that the evolution of plasma cell tumors may arise from either the lymphoma microenvironment or the systemic immune status. In cases of coexistence of AITL and plasma cell tumors, the treatment containing anti-MM drugs such as lenalidomide was usually recommended and might bring therapeutic benefits. Careful identification of monoclonal plasma-cell populations is therefore important for accurate diagnosis and individualized management of AITL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.